Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
801-820 of 3,900 trials

DLBCL Treatment: Dexrazoxane for Heart Protection

We are studying whether dexrazoxane can help prevent heart problems in patients with diffuse large B-cell lymphoma receiving chemotherapy. This trial will also compare treatment responses and monitor any side effects.

Diffuse Large B-Cell Lymphoma3-6 monthsConfirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesCardiologyOncology

Nutrition Timing After Major Abdominal Surgery

We are comparing early versus delayed nutrition support for patients recovering from major emergency abdominal surgery. The goal is to see which approach may lower the risk of infections after surgery.

Major Emergency Abdominal Surgery≤3 monthsMonitoring phase (IV)No PlaceboInvestigational MedicinesGastroenterology

Acute Myeloid Leukemia: Cobicistat with Venetoclax and Azacitidine

We are studying a new treatment combination for patients with acute myeloid leukemia who cannot receive intensive chemotherapy. This trial aims to see if adding cobicistat to venetoclax and azacitidine improves survival and treatment outcomes.

Acute Myeloid Leukaemia3-6 monthsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboStandard MedicinesInternal MedicineOncology

Metastatic Breast Cancer: Sacituzumab Govitecan Study

We are analyzing how well sacituzumab govitecan works for patients with advanced breast cancer. The study will also assess safety and explore biomarkers that may predict treatment response.

Locally Advanced or Metastatic Hormone Receptor Positive Breast Cancer6-12 monthsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesOncology

Multiple Sclerosis: Annual vs. Semi-Annual Ocrelizumab Infusions

We are comparing the effects of annual and semi-annual infusions of ocrelizumab in patients with active multiple sclerosis. The goal is to see which schedule better prevents disease activity over two years.

Multiple Sclerosis1-2 yearsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesNeurology

Stomach Cancer: MK-2870 Treatment Study

We are comparing a new treatment called MK-2870 to standard care for people with advanced stomach cancer. The goal is to see if MK-2870 can improve survival and manage symptoms better.

Adenocarcinoma of the Gastroesophageal Junction>2 yearsConfirmation phase (III)6-10 visitsInvestigational MedicinesCost ReimbursementGastroenterologyOncology

Chronic Rhinosinusitis: Mepolizumab and Nasal Polypectomy Study

We are investigating whether combining Mepolizumab with in-office nasal polypectomy can improve quality of life for patients with chronic rhinosinusitis. The study will assess symptom relief and safety over time.

Chronic Rhinosinusitis with Nasal Polyps6-12 monthsMonitoring phase (IV)11-15 visitsNo PlaceboStandard MedicinesAllergologyOtolaryngology

Memory Disorders: Evaluating Tau PET Imaging

We are studying whether tau PET can improve diagnosis for patients with memory problems. This trial compares its effectiveness to more common and affordable diagnostic tools.

Mild Cognitive Impairment and Dementia1-2 yearsEfficacy phase (II)Confirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesCost ReimbursementNeurology

Advanced Solid Tumors: M1774 and PLX038 Combination

We are investigating whether a new oral medication combined with another drug can help patients with advanced solid tumors. This study aims to explore the effectiveness of this treatment approach.

Metastatic Triple Negative Breast Cancer>2 yearsSafety phase (I)Oncology

Follicular Lymphoma: Mosunetuzumab and Lenalidomide Study

We are evaluating a new combination treatment for people with untreated follicular lymphoma to see if it works better than standard chemotherapy. This study aims to improve patient outcomes and quality of life.

Follicular Lymphoma>2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboStandard MedicinesHematologyOncology

Heart Attack Prevention: Selatogrel Study

We are studying whether self-administering selatogrel can help prevent further heart attacks in individuals with a recent heart attack history. The trial also looks at the safety of this self-administration.

Heart Attack>2 yearsConfirmation phase (III)≤5 visitsInvestigational MedicinesCost ReimbursementPartially RemoteCardiologyInternal Medicine

Chronic Lymphocytic Leukemia: Venetoclax and Acalabrutinib Treatment

We are studying a combination of venetoclax and acalabrutinib for patients with CLL who have relapsed after previous treatment. The goal is to see if this combination can help achieve better disease control and improve quality of life.

Chronic Lymphocytic LeukemiaPatients with Relapsed CLL>2 yearsEfficacy phase (II)>20 visitsNo PlaceboStandard MedicinesHematologyOncology

Erosive Esophagitis: NEXIUM for Kids

We are studying whether NEXIUM can help maintain healing in children aged 1 to 11 with erosive esophagitis. This trial also looks at how well the medication works and any symptoms during treatment.

Erosive Esophagitis6-12 monthsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteGastroenterologyPediatrics

Blood Cancer Treatment: ABBV-319 Study

We are examining how a new intravenous treatment affects adults with relapsed or refractory diffuse large B-cell lymphoma, follicular lymphoma, or chronic lymphocytic leukemia. The study looks at potential side effects and changes in disease activity.

Follicular LymphomaChronic Lymphocytic LeukemiaDiffuse Large B-Cell Lymphoma>2 yearsSafety phase (I)Oncology

Bacterial Brain Abscess: Oral vs. IV Antibiotics

We are studying whether oral antibiotics are as effective as IV antibiotics for treating bacterial brain abscesses. This trial will help us understand the best treatment options and their impact on recovery and quality of life.

Brain Abscess>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesInfectious DiseasesNeurology

Small Bowel Adenocarcinoma: FOLFIRINOX vs. FOLFOX

We are studying two chemotherapy treatments for patients with locally advanced or metastatic small bowel adenocarcinoma. The goal is to find out which treatment helps patients live longer without their cancer worsening.

Small Bowel Adenocarcinoma>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesGastroenterologyOncology

Sparsentan for Pediatric Kidney Diseases

We are studying a new oral treatment for children with certain kidney diseases to see if it is safe and effective. The trial will also evaluate how well children tolerate the medication and its impact on kidney function.

Proteinuric Glomerular Diseases>2 yearsEfficacy phase (II)11-15 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteNephrologyPediatrics

Primary Aldosteronism: [68Ga]Ga-PentixaFor PET Imaging Study

We are evaluating a new imaging method to help identify how adrenal glands secrete aldosterone in patients with primary aldosteronism. This may improve diagnosis and treatment options for those affected.

Primary Hyperaldosteronism>2 yearsEfficacy phase (II)Confirmation phase (III)≤5 visitsNo PlaceboInvestigational MedicinesPartially RemoteEndocrinology

Acyclovir for ICU Patients with Herpes Simplex Virus Reactivation

We are studying whether acyclovir can help reduce mortality and improve recovery in intubated patients with Herpes simplex virus reactivation. This trial compares acyclovir to a placebo to see which treatment is more effective.

Herpes Simplex Reactivation>2 yearsConfirmation phase (III)Standard MedicinesInfectious DiseasesInternal Medicine

B-cell Non-Hodgkin Lymphoma: CARCIK-CD19 Cell Therapy

We are studying a new cell therapy for adults and children with relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia. The trial aims to evaluate the safety and effectiveness of this treatment.

B-cell Non-Hodgkin Lymphoma and Chronic Lymphocytic LeukemiaSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesHematologyOncology